[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI951024A0 - Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät - Google Patents

Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät

Info

Publication number
FI951024A0
FI951024A0 FI951024A FI951024A FI951024A0 FI 951024 A0 FI951024 A0 FI 951024A0 FI 951024 A FI951024 A FI 951024A FI 951024 A FI951024 A FI 951024A FI 951024 A0 FI951024 A0 FI 951024A0
Authority
FI
Finland
Prior art keywords
cytochrome
inhibitors
nitrogen
methods
substituted acridines
Prior art date
Application number
FI951024A
Other languages
English (en)
Swedish (sv)
Other versions
FI951024A (fi
Inventor
Thomas F Woolf
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/943,323 external-priority patent/US5422350A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of FI951024A publication Critical patent/FI951024A/fi
Publication of FI951024A0 publication Critical patent/FI951024A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
FI951024A 1992-09-10 1995-03-06 Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät FI951024A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/943,323 US5422350A (en) 1992-09-10 1992-09-10 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US08/100,917 US5466696A (en) 1992-09-10 1993-08-09 Tacrine and cytochrome P450 oxidase inhibitors and methods of use
PCT/US1993/008459 WO1994005296A2 (en) 1992-09-10 1993-09-08 Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine

Publications (2)

Publication Number Publication Date
FI951024A FI951024A (fi) 1995-03-06
FI951024A0 true FI951024A0 (fi) 1995-03-06

Family

ID=26797688

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951024A FI951024A0 (fi) 1992-09-10 1995-03-06 Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät

Country Status (18)

Country Link
US (1) US5466696A (fi)
EP (1) EP0659082B1 (fi)
JP (1) JPH08501105A (fi)
KR (1) KR950703339A (fi)
AT (1) ATE212845T1 (fi)
AU (1) AU669586B2 (fi)
CA (1) CA2141425A1 (fi)
CZ (1) CZ48095A3 (fi)
DE (1) DE69331546T2 (fi)
DK (1) DK0659082T3 (fi)
ES (1) ES2171419T3 (fi)
FI (1) FI951024A0 (fi)
HU (1) HU217845B (fi)
NO (1) NO307955B1 (fi)
NZ (1) NZ256940A (fi)
PT (1) PT659082E (fi)
SK (1) SK26495A3 (fi)
WO (1) WO1994005296A2 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2285948A1 (en) * 1997-04-28 1998-11-05 The University Of British Columbia Method and composition for modulating amyloidosis
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU779900B2 (en) * 1999-07-22 2005-02-17 Organogenesis Inc. In vivo induction for enhanced function of isolated hepatocytes
JP4355212B2 (ja) * 2001-12-21 2009-10-28 オーガノジェネシス インコーポレーテッド 細胞培養及び臓器補助用の可変容量チャンバ
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US7583551B2 (en) 2004-03-10 2009-09-01 Micron Technology, Inc. Power management control and controlling memory refresh operations
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
WO2008153722A1 (en) * 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
DE1643240A1 (de) * 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
SU429813A1 (ru) * 1971-08-20 1974-05-30 Способ лечения туберкулеза легких
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
SU789112A1 (ru) * 1979-04-12 1980-12-23 Научно-исследовательский институт экспериментальной и клинической медицины Способ лечени экстрасистолической аритмии у детей
SU827081A1 (ru) * 1979-06-05 1981-05-07 Донецкий Медицинский Институт Им.M.Горького Способ лечени вазомоторных головныхбОлЕй
GB2091249A (en) * 1980-12-23 1982-07-28 Fordonal Sa Xanthine derivatives
SU1049065A1 (ru) * 1981-01-09 1983-10-23 Andronova Liliya Z Способ лечени заикани
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
SU1156700A1 (ru) * 1982-01-19 1985-05-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени неврозов
SU1210789A1 (ru) * 1983-07-21 1986-02-15 Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова Способ диагностики функционального нарушени желудочной секреции
SU1196002A1 (ru) * 1984-06-28 1985-12-07 Запорожский государственный институт усовершенствования врачей им.М.Горького Способ лечени хронического сальпингоофорита
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4754050A (en) * 1984-10-25 1988-06-28 Hoechst-Roussel Pharmaceuticals, Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4835275A (en) * 1984-10-25 1989-05-30 Hoechst-Roussel Pharmaceuticals, Inc. Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds
EP0179383B1 (en) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
SU1537252A1 (ru) * 1985-03-28 1990-01-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени парестезий полости рта
SU1416125A1 (ru) * 1986-02-21 1988-08-15 Одесский Научно-Исследовательский Институт Курортологии Способ лечени заболеваний суставов
SU1389050A1 (ru) * 1986-07-28 1990-08-30 Niiex Meditsiny An Sssr Cпocoб лeчehия aлkoгoлизma
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
FI90417C (fi) * 1988-11-16 1994-02-10 Hoechst Marion Roussel Inc Menetelmä terapeuttisesti aktiivisten hydroksi-1,2,3,4-tetrahydroaminoakridiinien valmistamiseksi
GB8827704D0 (en) * 1988-11-28 1988-12-29 Fujisawa Pharmaceutical Co New acridine derivatives & processes for their production
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

Also Published As

Publication number Publication date
DE69331546T2 (de) 2002-10-31
DK0659082T3 (da) 2002-06-17
US5466696A (en) 1995-11-14
KR950703339A (ko) 1995-09-20
DE69331546D1 (de) 2002-03-21
WO1994005296A2 (en) 1994-03-17
SK26495A3 (en) 1996-05-08
AU5290593A (en) 1994-03-29
FI951024A (fi) 1995-03-06
WO1994005296A3 (en) 1994-04-28
JPH08501105A (ja) 1996-02-06
AU669586B2 (en) 1996-06-13
EP0659082A1 (en) 1995-06-28
CZ48095A3 (en) 1995-12-13
PT659082E (pt) 2002-07-31
HUT70979A (en) 1995-11-28
HU217845B (hu) 2000-04-28
NO950909L (no) 1995-03-09
NZ256940A (en) 1996-03-26
NO307955B1 (no) 2000-06-26
ATE212845T1 (de) 2002-02-15
EP0659082B1 (en) 2002-02-06
HU9500704D0 (en) 1995-04-28
NO950909D0 (no) 1995-03-09
ES2171419T3 (es) 2002-09-16
CA2141425A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE209483T1 (de) Behandlung von multipler sklerose
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2&#39;-deoksi-nükleosidlerin kullanımı
DE69532961D1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
FI951024A (fi) Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät
DE69402173D1 (de) Hemmung von Thrombin
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE3686582D1 (de) Behandlung einer krankheit vom aids-typ.
NO994330L (no) Metode for behandling av en tumor
DE69834724D1 (de) Behandlung von Darm- oder Blasenentzündungen
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
ATE219929T1 (de) Hautbleichende dermatologische und/oder kosmetische zusammensetzung
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ATE229343T1 (de) Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
UA40974A (uk) Спосіб лікування міопії у дітей та підлітків
MD346G2 (ro) Picoliden-4-izonicotinoilhidrazona dihidrată cu activitate tuberculostatică
KR940003550A (ko) 노인성 치매 예방 및 치료방법
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.